drugset / Trial / NCT06868576
PPOS Protocol Versus GnRH Anatagonist for Expected Normal Responder Patients Undergoing ART : a Randomized Clinical Trial
RandomizedParallel-groupOpen-labelTreatment
Summary
The aim of this study is to compare the efficacy and safety of Progestin-Primed Ovarian Stimulation (PPOS) protocol versus the fixed GnRH antagonist protocol in expected normal responder patients undergoing intracytoplasmic sperm injection (ICSI) with frozen-thawed embryo transfer (FET). By evaluating key clinical outcomes, including ovarian response, embryological parameters, and pregnancy rates, this study seeks to determine the relative advantages and limitations of each protocol.
Timeline
- Start
- 2023-01-03
- Primary completion
- 2024-10-31
- Completion
- 2025-02-28
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Cetrorelix | Other / unclassified | — | — |
| Subject | Dydrogesterone | Other / unclassified | 20 mg | Oral |
Indications
No indication recorded.